GlassScriptPhysician profile
Laquisa Hill
NPI 1932491438
$32,423.98
in general payments reported to CMS, 2019-2025
31 companies · $5,312 in 2025
The $5,312 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,677 · 2020: $1,613 · 2021: $1,208 · 2022: $1,027 · 2023: $15K · 2024: $6,511 · 2025: $5,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $3,814 · Honoraria: $3,750 · Food and Beverage: $2,513 · Consulting Fee: $325 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,478.00 |
| Travel and Lodging | $3,813.68 |
| Honoraria | $3,750.00 |
| Food and Beverage | $2,512.95 |
| Consulting Fee | $325.00 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $14,676.85 | 2023-2024 | Yescarta |
| Sanofi-Aventis U.S. LLC | $5,465.16 | 2021-2024 | |
| Pierre Fabre Pharmaceuticals, INC. | $4,573.66 | 2025 | |
| Incyte Corporation | $2,430.95 | 2019-2021 | |
| National Marrow Donor Program | $1,500.39 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $869.55 | 2019-2025 | Calquence |
| Celgene Corporation | $639.60 | 2019-2025 | Onureg, Abecma, Breyanzi |
| E.R. Squibb & Sons, L.L.C. | $213.83 | 2022 | |
| Astellas Pharma US INC | $203.69 | 2019-2021 | |
| Medexus Pharma, INC. | $178.34 | 2022 | |
| Alexion Pharmaceuticals, INC. | $175.00 | 2025 | Ultomiris |
| Janssen Scientific Affairs, LLC | $150.00 | 2024 | Talvey |
| Genzyme Corporation | $143.54 | 2019-2020 | |
| Genentech USA, INC. | $133.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $116.10 | 2019 | |
| Daiichi Sankyo INC. | $112.66 | 2024 | Vanflyta |
| Secura Bio, INC. | $108.60 | 2025 | Copiktra |
| Sobi, INC | $107.38 | 2022 | |
| Janssen Biotech, INC. | $91.35 | 2021-2022 | |
| Genmab U.S., INC. | $77.27 | 2025 | Epkinly |
| Dova Pharmaceuticals | $55.86 | 2019 | |
| Amgen INC. | $54.52 | 2019 | |
| Servier Pharmaceuticals LLC | $49.53 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $49.07 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $35.93 | 2019-2023 | Prevymis |
| Takeda Pharmaceuticals U.S.A., INC. | $28.38 | 2019 | |
| Coherus Oncology, INC. | $21.51 | 2021 | |
| Seagen INC. | $20.02 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laquisa Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.